1. Medtech Insight
  2. >>Geography

Next Steps For NEST: Planning Board Lays Out Launch Strategy For Evaluation System

A public-private National Evaluation System for health Technology (NEST) is gathering momentum following a recent funding agreement in the draft Medical Device User Fee Act IV deal. A planning board tasked with developing a NEST coordinating center has outlined projects to get the system off the ground. Also: Listen to our podcast interview with Mark McClellan about the project.

The Duke-Margolis Center for Health Policy has released a third report outlining steps to make a public-private National Evaluation System for health Technology (NEST) a reality. The center, which houses the planning board tasked with developing a coordinating center for NEST, proposed demonstration projects that would be phased in two stages to show how best to share data and develop best practices.

US FDA is a major advocate for NEST, stating the program would improve surveillance of medical products on the market...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United States

More from North America

Innovative Wants Injunction Against J&J Subsidiary After $442M Antitrust Verdict

 
• By Elizabeth Orr

Innovative Healthcare is asking for a permanent injunction against Johnson & Johnson subsidiary Biosense Webster after winning a $442 million antitrust verdict. The injunction aims to prevent continued anticompetitive practices in the electrophysiology catheter market.

Increasing Safety Concerns Spur Scrutiny of Device Plastics Use

 
• By Elizabeth Orr

With new regulations limiting the use of plastics popping up worldwide, the medtech industry sees arguments on both sides. Some argue hasty bans of PFAS ("forever chemicals") would harm patients, while others say phthalates should be phased out to protect the public.

With LDT Rule DOA, Could FDA Shift Focus To RUOs?

 
• By Brian Bossetta

Now that the US FDA has chosen not to appeal a March ruling effectively killing the agency’s efforts to regulate lab-developed tests as medical devices, will the agency adopt a different strategy to flex its regulatory muscle?